ALK translocation renal cell carcinoma - Revision history

Michael: redirect

2025-09-26T21:47:54Z

redirect

← Older revision		Revision as of 21:47, 26 September 2025
Line 1:		Line 1:
	~~{{ Infobox diagnosis~~		#redirect [[ALK-rearranged renal cell carcinoma]]
	~~\| Name = {{PAGENAME}}~~
	~~\| Image =~~
	~~\| Width =~~
	~~\| Caption =~~
	~~\| Synonyms =~~
	~~\| Micro = mixed morphology, +/-papillae, +/-myxoid change~~
	~~\| Subtypes =~~
	~~\| LMDDx = [[papillary renal cell carcinoma]], [[unclassified renal cell carcinoma]], [[clear cell renal cell carcinoma]], [[SMARCB1-deficient renal medullary carcinoma]],~~ [[~~renal mucinous tubular and spindle cell carcinoma]]~~
	~~\| Stains =~~
	~~\| IHC = ALK +ve~~
	~~\| EM =~~
	~~\| Molecular = ALK rearranagement~~
	~~\| IF =~~
	~~\| Gross =~~
	~~\| Grossing = [[total nephrectomy for tumour grossing]], [[partial nephrectomy grossing]]~~
	~~\| Staging = [[kidney cancer staging]]~~
	~~\| Site = [[kidney]] - see ''[[kidney tumours]]''~~
	~~\| Assdx =~~
	~~\| Syndromes =~~
	~~\| Clinicalhx =~~
	~~\| Signs =~~
	~~\| Symptoms =~~
	~~\| Prevalence = very rare~~
	~~\| Bloodwork =~~
	~~\| Rads =~~
	~~\| Endoscopy =~~
	~~\| Prognosis =~~
	~~\| Other =~~
	~~\| ClinDDx =~~
	~~\| Tx = may respond to ALK inhibitors~~
	}}
	~~'''ALK translocation renal cell carcinoma''', also '''~~ALK-rearranged renal cell carcinoma~~''' and '''ALK-positive renal cell carcinoma''', is a type of [[renal cell carcinoma]] recognized by the WHO.~~

	~~==General==~~
	*Extremely rare.
	**One case was identified in 829 consecutively screened Korean patients.<ref name=pmid24255633>{{Cite journal \| last1 = Lee \| first1 = C. \| last2 = Park \| first2 = JW. \| last3 = Suh \| first3 = JH. \| last4 = Nam \| first4 = KH. \| last5 = Moon \| first5 = KC. \| title = ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. \| journal = Korean J Pathol \| volume = 47 \| issue = 5 \| pages = 452-7 \| month = Oct \| year = 2013 \| doi = 10.4132/KoreanJPathol.2013.47.5.452 \| PMID = 24255633 }}</ref>
	**A second series described 8 in 276 cases on a microarray.<ref name=pmid38039739>{{cite journal \|authors=Doğan K, Onder E \|title=ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey \|journal=Pathol Res Pract \|volume=253 \|issue= \|pages=154951 \|date=January 2024 \|pmid=38039739 \|doi=10.1016/j.prp.2023.154951 \|url=}}</ref>
	**In 2016, less than 17 cases reported.<ref name=pmid27554841>{{Cite journal \| last1 = Jeanneau \| first1 = M. \| last2 = Gregoire \| first2 = V. \| last3 = Desplechain \| first3 = C. \| last4 = Escande \| first4 = F. \| last5 = Tica \| first5 = DP. \| last6 = Aubert \| first6 = S. \| last7 = Leroy \| first7 = X. \| title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. \| journal = Pathol Res Pract \| volume = 212 \| issue = 11 \| pages = 1064-1066 \| month = Nov \| year = 2016 \| doi = 10.1016/j.prp.2016.07.015 \| PMID = 27554841 }}</ref>
	*May respond to [[ALK inhibitors]] such as alectinib<ref name=pmid29685646>{{Cite journal \| last1 = Pal \| first1 = SK. \| last2 = Bergerot \| first2 = P. \| last3 = Dizman \| first3 = N. \| last4 = Bergerot \| first4 = C. \| last5 = Adashek \| first5 = J. \| last6 = Madison \| first6 = R. \| last7 = Chung \| first7 = JH. \| last8 = Ali \| first8 = SM. \| last9 = Jones \| first9 = JO. \| title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. \| journal = Eur Urol \| volume = 74 \| issue = 1 \| pages = 124-128 \| month = 07 \| year = 2018 \| doi = 10.1016/j.eururo.2018.03.032 \| PMID = 29685646 }}</ref> or crizotinib.<ref name=pmid27554841>{{Cite journal \| last1 = Jeanneau \| first1 = M. \| last2 = Gregoire \| first2 = V. \| last3 = Desplechain \| first3 = C. \| last4 = Escande \| first4 = F. \| last5 = Tica \| first5 = DP. \| last6 = Aubert \| first6 = S. \| last7 = Leroy \| first7 = X. \| title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. \| journal = Pathol Res Pract \| volume = 212 \| issue = 11 \| pages = 1064-1066 \| month = Nov \| year = 2016 \| doi = 10.1016/j.prp.2016.07.015 \| PMID = 27554841 }}</ref>

	~~==Microscopic==~~
	~~Features:~~
	*Mix of morphologies - including:
	**[[Papillary renal cell carcinoma]].<ref name=pmid24255633/>
	**[[Renal cell carcinoma with rhabdoid morphology\|Rhabdoid change]].<ref name=pmid26017874>{{Cite journal \| last1 = Kuroda \| first1 = N. \| last2 = Karashima \| first2 = T. \| last3 = Inoue \| first3 = K. \| last4 = Kasajima \| first4 = A. \| last5 = Ohe \| first5 = C. \| last6 = Kawakami \| first6 = F. \| last7 = Mikami \| first7 = S. \| last8 = Matsuura \| first8 = K. \| last9 = Moriyama \| first9 = M. \| title = Review of renal cell carcinoma with rhabdoid features with focus on clinical and pathobiological aspects. \| journal = Pol J Pathol \| volume = 66 \| issue = 1 \| pages = 3-8 \| month = Mar \| year = 2015 \| doi = \| PMID = 26017874 }}</ref>
	**[[Renal cell carcinoma with sarcomatoid differentiation\|Sarcomatoid change]].
	**"[[Unclassified renal cell carcinoma]]".

	~~DDx:~~
	*[[Papillary renal cell carcinoma]] - especially what used to be known as "type 2".<ref name=pmid24255633/>
	*[[Unclassified renal cell carcinoma]]
	*[[Renal medullary carcinoma]].
	*[[Clear cell renal cell carcinoma]].<ref name=pmid38039739/>
	*[[Renal mucinous tubular and spindle cell carcinoma]].<ref>{{cite journal \|authors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S \|title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report \|journal=Diagn Pathol \|volume=17 \|issue=1 \|pages=52 \|date=June 2022 \|pmid=35718773 \|pmc=9206751 \|doi=10.1186/s13000-022-01238-z \|url=}}</ref>

	~~==IHC==~~
	Features:<ref>{{Cite journal \| last1 = Jeanneau \| first1 = M. \| last2 = Gregoire \| first2 = V. \| last3 = Desplechain \| first3 = C. \| last4 = Escande \| first4 = F. \| last5 = Tica \| first5 = DP. \| last6 = Aubert \| first6 = S. \| last7 = Leroy \| first7 = X. \| title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. \| journal = Pathol Res Pract \| volume = 212 \| issue = 11 \| pages = 1064-1066 \| month = Nov \| year = 2016 \| doi = 10.1016/j.prp.2016.07.015 \| PMID = 27554841 }}</ref>
	*L-ALK +ve. ‡
	*PAX8 +ve.
	*Vimentin +ve (diffuse).
	*CK7 +ve (focal).
	*[[SMARCB1]] normal nuclear staining.{{fact}}

	‡ There are different clones for ALK; they may be called ''ALK1'' (used in lymphoma) and ''L-ALK'' (used in lung cancer). In the context of RCC, the ALK clone for lung cancer (e.g. D5F3) should be used.<ref>{{cite journal \|authors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S \|title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report \|journal=Diagn Pathol \|volume=17 \|issue=1 \|pages=52 \|date=June 2022 \|pmid=35718773 \|pmc=9206751 \|doi=10.1186/s13000-022-01238-z \|url=}}</ref>

	~~==Molecular==~~
	*ALK rearrangement.

	~~==See also==~~
	*[[Vancouver classification]].
	*[[Kidney tumours]].
	*[[Lung carcinoma with ALK rearrangement]].

	~~==References==~~
	~~{{Reflist\|2}}~~

	~~[[Category:Kidney tumours]]~~
	~~[[Category:Diagnosis~~]]

Michael at 21:38, 26 September 2025

2025-09-26T21:38:54Z

← Older revision		Revision as of 21:38, 26 September 2025
Line 74:		Line 74:

	==References==		==References==
	{{Reflist\|1}}		{{Reflist\|2}}

	[[Category:Kidney tumours]]		[[Category:Kidney tumours]]
			[[Category:Diagnosis]]

Michael: /* IHC */

2025-09-26T21:38:11Z

IHC

← Older revision		Revision as of 21:38, 26 September 2025
Line 63:		Line 63:
	*[[SMARCB1]] normal nuclear staining.{{fact}}		*[[SMARCB1]] normal nuclear staining.{{fact}}

	‡ There are different clones for ALK~~. They~~ may be called ''ALK1'' (used of lymphoma) and ''L-ALK'' (used of lung cancer). In the context of RCC, the ALK clone for lung cancer (e.g. D5F3) should be used.<ref>{{cite journal \|authors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S \|title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report \|journal=Diagn Pathol \|volume=17 \|issue=1 \|pages=52 \|date=June 2022 \|pmid=35718773 \|pmc=9206751 \|doi=10.1186/s13000-022-01238-z \|url=}}</ref>		‡ There are different clones for ALK; they may be called ''ALK1'' (used in lymphoma) and ''L-ALK'' (used in lung cancer). In the context of RCC, the ALK clone for lung cancer (e.g. D5F3) should be used.<ref>{{cite journal \|authors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S \|title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report \|journal=Diagn Pathol \|volume=17 \|issue=1 \|pages=52 \|date=June 2022 \|pmid=35718773 \|pmc=9206751 \|doi=10.1186/s13000-022-01238-z \|url=}}</ref>

	==Molecular==		==Molecular==

Michael: /* IHC */

2025-09-26T21:37:33Z

IHC

← Older revision		Revision as of 21:37, 26 September 2025
Line 63:		Line 63:
	*[[SMARCB1]] normal nuclear staining.{{fact}}		*[[SMARCB1]] normal nuclear staining.{{fact}}

	‡ There are different clones for ALK. ~~The~~ ALK clone for lung cancer (e.g. D5F3) should be used.<ref>{{cite journal \|authors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S \|title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report \|journal=Diagn Pathol \|volume=17 \|issue=1 \|pages=52 \|date=June 2022 \|pmid=35718773 \|pmc=9206751 \|doi=10.1186/s13000-022-01238-z \|url=}}</ref>		‡ There are different clones for ALK. They may be called ''ALK1'' (used of lymphoma) and ''L-ALK'' (used of lung cancer). In the context of RCC, the ALK clone for lung cancer (e.g. D5F3) should be used.<ref>{{cite journal \|authors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S \|title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report \|journal=Diagn Pathol \|volume=17 \|issue=1 \|pages=52 \|date=June 2022 \|pmid=35718773 \|pmc=9206751 \|doi=10.1186/s13000-022-01238-z \|url=}}</ref>

	==Molecular==		==Molecular==

Michael: /* IHC */

2025-09-26T21:26:50Z

IHC

← Older revision		Revision as of 21:26, 26 September 2025
Line 57:		Line 57:
	==IHC==		==IHC==
	Features:<ref>{{Cite journal \| last1 = Jeanneau \| first1 = M. \| last2 = Gregoire \| first2 = V. \| last3 = Desplechain \| first3 = C. \| last4 = Escande \| first4 = F. \| last5 = Tica \| first5 = DP. \| last6 = Aubert \| first6 = S. \| last7 = Leroy \| first7 = X. \| title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. \| journal = Pathol Res Pract \| volume = 212 \| issue = 11 \| pages = 1064-1066 \| month = Nov \| year = 2016 \| doi = 10.1016/j.prp.2016.07.015 \| PMID = 27554841 }}</ref>		Features:<ref>{{Cite journal \| last1 = Jeanneau \| first1 = M. \| last2 = Gregoire \| first2 = V. \| last3 = Desplechain \| first3 = C. \| last4 = Escande \| first4 = F. \| last5 = Tica \| first5 = DP. \| last6 = Aubert \| first6 = S. \| last7 = Leroy \| first7 = X. \| title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. \| journal = Pathol Res Pract \| volume = 212 \| issue = 11 \| pages = 1064-1066 \| month = Nov \| year = 2016 \| doi = 10.1016/j.prp.2016.07.015 \| PMID = 27554841 }}</ref>
	*ALK +ve.		*L-ALK +ve. ‡
	*PAX8 +ve.		*PAX8 +ve.
	*Vimentin +ve (diffuse).		*Vimentin +ve (diffuse).
	*CK7 +ve (focal).		*CK7 +ve (focal).
	*[[SMARCB1]] normal nuclear staining.{{fact}}		*[[SMARCB1]] normal nuclear staining.{{fact}}

			‡ There are different clones for ALK. The ALK clone for lung cancer (e.g. D5F3) should be used.<ref>{{cite journal \|authors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S \|title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report \|journal=Diagn Pathol \|volume=17 \|issue=1 \|pages=52 \|date=June 2022 \|pmid=35718773 \|pmc=9206751 \|doi=10.1186/s13000-022-01238-z \|url=}}</ref>

	==Molecular==		==Molecular==

Michael at 22:50, 29 May 2025

2025-05-29T22:50:07Z

← Older revision		Revision as of 22:50, 29 May 2025
Line 53:		Line 53:
	*[[Renal medullary carcinoma]].		*[[Renal medullary carcinoma]].
	*[[Clear cell renal cell carcinoma]].<ref name=pmid38039739/>		*[[Clear cell renal cell carcinoma]].<ref name=pmid38039739/>
	*[[Renal mucinous tubular and spindle cell carcinoma]].<ref>{{cite journal \|~~vauthors~~=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S \|title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report \|journal=Diagn Pathol \|volume=17 \|issue=1 \|pages=52 \|date=June 2022 \|pmid=35718773 \|pmc=9206751 \|doi=10.1186/s13000-022-01238-z \|url=}}</ref>		*[[Renal mucinous tubular and spindle cell carcinoma]].<ref>{{cite journal \|authors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S \|title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report \|journal=Diagn Pathol \|volume=17 \|issue=1 \|pages=52 \|date=June 2022 \|pmid=35718773 \|pmc=9206751 \|doi=10.1186/s13000-022-01238-z \|url=}}</ref>

	==IHC==		==IHC==

Michael at 22:49, 29 May 2025

2025-05-29T22:49:25Z

← Older revision		Revision as of 22:49, 29 May 2025
Line 7:		Line 7:
	\| Micro = mixed morphology, +/-papillae, +/-myxoid change		\| Micro = mixed morphology, +/-papillae, +/-myxoid change
	\| Subtypes =		\| Subtypes =
	\| LMDDx = [[papillary renal cell carcinoma]], [[unclassified renal cell carcinoma]], [[clear cell renal cell carcinoma]], [[SMARCB1-deficient renal medullary carcinoma]]		\| LMDDx = [[papillary renal cell carcinoma]], [[unclassified renal cell carcinoma]], [[clear cell renal cell carcinoma]], [[SMARCB1-deficient renal medullary carcinoma]], [[renal mucinous tubular and spindle cell carcinoma]]
	\| Stains =		\| Stains =
	\| IHC = ALK +ve		\| IHC = ALK +ve
Line 53:		Line 53:
	*[[Renal medullary carcinoma]].		*[[Renal medullary carcinoma]].
	*[[Clear cell renal cell carcinoma]].<ref name=pmid38039739/>		*[[Clear cell renal cell carcinoma]].<ref name=pmid38039739/>
			*[[Renal mucinous tubular and spindle cell carcinoma]].<ref>{{cite journal \|vauthors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S \|title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report \|journal=Diagn Pathol \|volume=17 \|issue=1 \|pages=52 \|date=June 2022 \|pmid=35718773 \|pmc=9206751 \|doi=10.1186/s13000-022-01238-z \|url=}}</ref>

	==IHC==		==IHC==

Michael at 14:39, 16 December 2024

2024-12-16T14:39:48Z

← Older revision		Revision as of 14:39, 16 December 2024
Line 61:		Line 61:
	*CK7 +ve (focal).		*CK7 +ve (focal).
	*[[SMARCB1]] normal nuclear staining.{{fact}}		*[[SMARCB1]] normal nuclear staining.{{fact}}

			==Molecular==
			*ALK rearrangement.

	==See also==		==See also==

Michael at 14:37, 16 December 2024

2024-12-16T14:37:36Z

← Older revision		Revision as of 14:37, 16 December 2024
Line 14:		Line 14:
	\| IF =		\| IF =
	\| Gross =		\| Gross =
	\| Grossing =		\| Grossing = [[total nephrectomy for tumour grossing]], [[partial nephrectomy grossing]]
	\| Staging =		\| Staging = [[kidney cancer staging]]
	\| Site = [[kidney]] - see ''[[kidney tumours]]''		\| Site = [[kidney]] - see ''[[kidney tumours]]''
	\| Assdx =		\| Assdx =

Michael: infobox

2024-12-16T14:36:37Z

infobox

← Older revision		Revision as of 14:36, 16 December 2024
Line 1:		Line 1:
			{{ Infobox diagnosis
			\| Name = {{PAGENAME}}
			\| Image =
			\| Width =
			\| Caption =
			\| Synonyms =
			\| Micro = mixed morphology, +/-papillae, +/-myxoid change
			\| Subtypes =
			\| LMDDx = [[papillary renal cell carcinoma]], [[unclassified renal cell carcinoma]], [[clear cell renal cell carcinoma]], [[SMARCB1-deficient renal medullary carcinoma]]
			\| Stains =
			\| IHC = ALK +ve
			\| EM =
			\| Molecular = ALK rearranagement
			\| IF =
			\| Gross =
			\| Grossing =
			\| Staging =
			\| Site = [[kidney]] - see ''[[kidney tumours]]''
			\| Assdx =
			\| Syndromes =
			\| Clinicalhx =
			\| Signs =
			\| Symptoms =
			\| Prevalence = very rare
			\| Bloodwork =
			\| Rads =
			\| Endoscopy =
			\| Prognosis =
			\| Other =
			\| ClinDDx =
			\| Tx = may respond to ALK inhibitors
			}}
	'''ALK translocation renal cell carcinoma''', also '''ALK-rearranged renal cell carcinoma''' and '''ALK-positive renal cell carcinoma''', is a type of [[renal cell carcinoma]] recognized by the WHO.		'''ALK translocation renal cell carcinoma''', also '''ALK-rearranged renal cell carcinoma''' and '''ALK-positive renal cell carcinoma''', is a type of [[renal cell carcinoma]] recognized by the WHO.

	==General==		==General==
	*Extremely rare.		*Extremely rare.
	**1 in 829 consecutively screened patients.<ref name=pmid24255633>{{Cite journal \| last1 = Lee \| first1 = C. \| last2 = Park \| first2 = JW. \| last3 = Suh \| first3 = JH. \| last4 = Nam \| first4 = KH. \| last5 = Moon \| first5 = KC. \| title = ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. \| journal = Korean J Pathol \| volume = 47 \| issue = 5 \| pages = 452-7 \| month = Oct \| year = 2013 \| doi = 10.4132/KoreanJPathol.2013.47.5.452 \| PMID = 24255633 }}</ref>		**One case was identified in 829 consecutively screened Korean patients.<ref name=pmid24255633>{{Cite journal \| last1 = Lee \| first1 = C. \| last2 = Park \| first2 = JW. \| last3 = Suh \| first3 = JH. \| last4 = Nam \| first4 = KH. \| last5 = Moon \| first5 = KC. \| title = ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. \| journal = Korean J Pathol \| volume = 47 \| issue = 5 \| pages = 452-7 \| month = Oct \| year = 2013 \| doi = 10.4132/KoreanJPathol.2013.47.5.452 \| PMID = 24255633 }}</ref>
	**A second series described 8 in 276 cases on a microarray.<ref name=pmid38039739>{{cite journal \|authors=Doğan K, Onder E \|title=ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey \|journal=Pathol Res Pract \|volume=253 \|issue= \|pages=154951 \|date=January 2024 \|pmid=38039739 \|doi=10.1016/j.prp.2023.154951 \|url=}}</ref>		**A second series described 8 in 276 cases on a microarray.<ref name=pmid38039739>{{cite journal \|authors=Doğan K, Onder E \|title=ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey \|journal=Pathol Res Pract \|volume=253 \|issue= \|pages=154951 \|date=January 2024 \|pmid=38039739 \|doi=10.1016/j.prp.2023.154951 \|url=}}</ref>
	**In 2016, less than 17 cases reported.<ref name=pmid27554841>{{Cite journal \| last1 = Jeanneau \| first1 = M. \| last2 = Gregoire \| first2 = V. \| last3 = Desplechain \| first3 = C. \| last4 = Escande \| first4 = F. \| last5 = Tica \| first5 = DP. \| last6 = Aubert \| first6 = S. \| last7 = Leroy \| first7 = X. \| title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. \| journal = Pathol Res Pract \| volume = 212 \| issue = 11 \| pages = 1064-1066 \| month = Nov \| year = 2016 \| doi = 10.1016/j.prp.2016.07.015 \| PMID = 27554841 }}</ref>		**In 2016, less than 17 cases reported.<ref name=pmid27554841>{{Cite journal \| last1 = Jeanneau \| first1 = M. \| last2 = Gregoire \| first2 = V. \| last3 = Desplechain \| first3 = C. \| last4 = Escande \| first4 = F. \| last5 = Tica \| first5 = DP. \| last6 = Aubert \| first6 = S. \| last7 = Leroy \| first7 = X. \| title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. \| journal = Pathol Res Pract \| volume = 212 \| issue = 11 \| pages = 1064-1066 \| month = Nov \| year = 2016 \| doi = 10.1016/j.prp.2016.07.015 \| PMID = 27554841 }}</ref>

← Older revision		Revision as of 21:47, 26 September 2025
Line 1:		Line 1:
	~~{{ Infobox diagnosis~~		#redirect [[ALK-rearranged renal cell carcinoma]]
	~~\| Name = {{PAGENAME}}~~
	~~\| Image =~~
	~~\| Width =~~
	~~\| Caption =~~
	~~\| Synonyms =~~
	~~\| Micro = mixed morphology, +/-papillae, +/-myxoid change~~
	~~\| Subtypes =~~
	~~\| LMDDx = [[papillary renal cell carcinoma]], [[unclassified renal cell carcinoma]], [[clear cell renal cell carcinoma]], [[SMARCB1-deficient renal medullary carcinoma]],~~ [[~~renal mucinous tubular and spindle cell carcinoma]]~~
	~~\| Stains =~~
	~~\| IHC = ALK +ve~~
	~~\| EM =~~
	~~\| Molecular = ALK rearranagement~~
	~~\| IF =~~
	~~\| Gross =~~
	~~\| Grossing = [[total nephrectomy for tumour grossing]], [[partial nephrectomy grossing]]~~
	~~\| Staging = [[kidney cancer staging]]~~
	~~\| Site = [[kidney]] - see ''[[kidney tumours]]''~~
	~~\| Assdx =~~
	~~\| Syndromes =~~
	~~\| Clinicalhx =~~
	~~\| Signs =~~
	~~\| Symptoms =~~
	~~\| Prevalence = very rare~~
	~~\| Bloodwork =~~
	~~\| Rads =~~
	~~\| Endoscopy =~~
	~~\| Prognosis =~~
	~~\| Other =~~
	~~\| ClinDDx =~~
	~~\| Tx = may respond to ALK inhibitors~~
	}}
	~~'''ALK translocation renal cell carcinoma''', also '''~~ALK-rearranged renal cell carcinoma~~''' and '''ALK-positive renal cell carcinoma''', is a type of [[renal cell carcinoma]] recognized by the WHO.~~

	~~==General==~~
	*Extremely rare.
	**One case was identified in 829 consecutively screened Korean patients.<ref name=pmid24255633>{{Cite journal \| last1 = Lee \| first1 = C. \| last2 = Park \| first2 = JW. \| last3 = Suh \| first3 = JH. \| last4 = Nam \| first4 = KH. \| last5 = Moon \| first5 = KC. \| title = ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. \| journal = Korean J Pathol \| volume = 47 \| issue = 5 \| pages = 452-7 \| month = Oct \| year = 2013 \| doi = 10.4132/KoreanJPathol.2013.47.5.452 \| PMID = 24255633 }}</ref>
	**A second series described 8 in 276 cases on a microarray.<ref name=pmid38039739>{{cite journal \|authors=Doğan K, Onder E \|title=ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey \|journal=Pathol Res Pract \|volume=253 \|issue= \|pages=154951 \|date=January 2024 \|pmid=38039739 \|doi=10.1016/j.prp.2023.154951 \|url=}}</ref>
	**In 2016, less than 17 cases reported.<ref name=pmid27554841>{{Cite journal \| last1 = Jeanneau \| first1 = M. \| last2 = Gregoire \| first2 = V. \| last3 = Desplechain \| first3 = C. \| last4 = Escande \| first4 = F. \| last5 = Tica \| first5 = DP. \| last6 = Aubert \| first6 = S. \| last7 = Leroy \| first7 = X. \| title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. \| journal = Pathol Res Pract \| volume = 212 \| issue = 11 \| pages = 1064-1066 \| month = Nov \| year = 2016 \| doi = 10.1016/j.prp.2016.07.015 \| PMID = 27554841 }}</ref>
	*May respond to [[ALK inhibitors]] such as alectinib<ref name=pmid29685646>{{Cite journal \| last1 = Pal \| first1 = SK. \| last2 = Bergerot \| first2 = P. \| last3 = Dizman \| first3 = N. \| last4 = Bergerot \| first4 = C. \| last5 = Adashek \| first5 = J. \| last6 = Madison \| first6 = R. \| last7 = Chung \| first7 = JH. \| last8 = Ali \| first8 = SM. \| last9 = Jones \| first9 = JO. \| title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. \| journal = Eur Urol \| volume = 74 \| issue = 1 \| pages = 124-128 \| month = 07 \| year = 2018 \| doi = 10.1016/j.eururo.2018.03.032 \| PMID = 29685646 }}</ref> or crizotinib.<ref name=pmid27554841>{{Cite journal \| last1 = Jeanneau \| first1 = M. \| last2 = Gregoire \| first2 = V. \| last3 = Desplechain \| first3 = C. \| last4 = Escande \| first4 = F. \| last5 = Tica \| first5 = DP. \| last6 = Aubert \| first6 = S. \| last7 = Leroy \| first7 = X. \| title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. \| journal = Pathol Res Pract \| volume = 212 \| issue = 11 \| pages = 1064-1066 \| month = Nov \| year = 2016 \| doi = 10.1016/j.prp.2016.07.015 \| PMID = 27554841 }}</ref>

	~~==Microscopic==~~
	~~Features:~~
	*Mix of morphologies - including:
	**[[Papillary renal cell carcinoma]].<ref name=pmid24255633/>
	**[[Renal cell carcinoma with rhabdoid morphology\|Rhabdoid change]].<ref name=pmid26017874>{{Cite journal \| last1 = Kuroda \| first1 = N. \| last2 = Karashima \| first2 = T. \| last3 = Inoue \| first3 = K. \| last4 = Kasajima \| first4 = A. \| last5 = Ohe \| first5 = C. \| last6 = Kawakami \| first6 = F. \| last7 = Mikami \| first7 = S. \| last8 = Matsuura \| first8 = K. \| last9 = Moriyama \| first9 = M. \| title = Review of renal cell carcinoma with rhabdoid features with focus on clinical and pathobiological aspects. \| journal = Pol J Pathol \| volume = 66 \| issue = 1 \| pages = 3-8 \| month = Mar \| year = 2015 \| doi = \| PMID = 26017874 }}</ref>
	**[[Renal cell carcinoma with sarcomatoid differentiation\|Sarcomatoid change]].
	**"[[Unclassified renal cell carcinoma]]".

	~~DDx:~~
	*[[Papillary renal cell carcinoma]] - especially what used to be known as "type 2".<ref name=pmid24255633/>
	*[[Unclassified renal cell carcinoma]]
	*[[Renal medullary carcinoma]].
	*[[Clear cell renal cell carcinoma]].<ref name=pmid38039739/>
	*[[Renal mucinous tubular and spindle cell carcinoma]].<ref>{{cite journal \|authors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S \|title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report \|journal=Diagn Pathol \|volume=17 \|issue=1 \|pages=52 \|date=June 2022 \|pmid=35718773 \|pmc=9206751 \|doi=10.1186/s13000-022-01238-z \|url=}}</ref>

	~~==IHC==~~
	Features:<ref>{{Cite journal \| last1 = Jeanneau \| first1 = M. \| last2 = Gregoire \| first2 = V. \| last3 = Desplechain \| first3 = C. \| last4 = Escande \| first4 = F. \| last5 = Tica \| first5 = DP. \| last6 = Aubert \| first6 = S. \| last7 = Leroy \| first7 = X. \| title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. \| journal = Pathol Res Pract \| volume = 212 \| issue = 11 \| pages = 1064-1066 \| month = Nov \| year = 2016 \| doi = 10.1016/j.prp.2016.07.015 \| PMID = 27554841 }}</ref>
	*L-ALK +ve. ‡
	*PAX8 +ve.
	*Vimentin +ve (diffuse).
	*CK7 +ve (focal).
	*[[SMARCB1]] normal nuclear staining.{{fact}}

	‡ There are different clones for ALK; they may be called ''ALK1'' (used in lymphoma) and ''L-ALK'' (used in lung cancer). In the context of RCC, the ALK clone for lung cancer (e.g. D5F3) should be used.<ref>{{cite journal \|authors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S \|title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report \|journal=Diagn Pathol \|volume=17 \|issue=1 \|pages=52 \|date=June 2022 \|pmid=35718773 \|pmc=9206751 \|doi=10.1186/s13000-022-01238-z \|url=}}</ref>

	~~==Molecular==~~
	*ALK rearrangement.

	~~==See also==~~
	*[[Vancouver classification]].
	*[[Kidney tumours]].
	*[[Lung carcinoma with ALK rearrangement]].

	~~==References==~~
	~~{{Reflist\|2}}~~

	~~[[Category:Kidney tumours]]~~
	~~[[Category:Diagnosis~~]]